Repotrectinib Safety Study for ROS1 and NTRK Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tracks how well and safely repotrectinib (a targeted cancer drug) works in Korean patients with specific types of lung cancer or solid tumors. You'd be monitored after starting this medication to help doctors understand how it affects people over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 19+ for lung cancer, or age 12+ for other solid tumors with NTRK gene fusions
- Confirmed diagnosis of either ROS1-positive advanced lung cancer OR solid tumor with NTRK gene fusion
- Gene fusion confirmed by lab testing at your treatment center
- Willingness to sign informed consent and be monitored during treatment
- Starting repotrectinib at doses approved by Korean health authorities
- No medical conditions that would make repotrectinib unsafe for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with advanced ROS1-positive non-small cell lung cancer who are taking targeted therapy. It aims to understand how well the treatment works in real life and is for those who haven't had any prior treatment for their lung cancer.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.